AD Pipeline Watch: Apogee’s APG777 Achieves a 71% Reduction in EASI Scores at 16 Weeks
Apogee Therapeutics, Inc.’s APG777 met all primary and key secondary endpoints and exceeded trial objectives, according to new 16-week data from Part A of the Phase 2 APEX clinical trial in patients with moderate-to-severe atopic dermatitis (AD).